Salzmann M, Leiter U, Loquai C, et al. - Researchers retrospectively assessed the efficacy of programmed cell death protein 1 (PD-1) inhibitors (pembrolizumab, nivolumab or cemiplimab) among patients from six German skin cancer centers who received these agents for treatment of advanced cutaneous squamous cell carcinoma (cSCC). There were 46 evaluable patients (median age: 76 years), of those, the overall response rate (RR) was estimated to be 58.7%, including 15.2% with complete response. Findings demonstrated that PD-1 inhibitors afford an efficient systemic therapy for advanced cSCC and were recommended as new standard of care. With high RRs and durable disease control, assessment of neoadjuvant and adjuvant regimens was advised.